(Reuters) - CTI BioPharma Corp said its experimental blood cancer treatment achieved the main goal of a late-stage study. Data from the study showed that the drug, pacritinib, was significantly better than the "best available therapy" as prescribed by the patients' physician to treat myelofibrosis. Myelofibrosis is a form of blood cancer that makes the bone marrow produce too much of any type of blood cells. (Reporting by Vidya L Nathan in Bengaluru; Editing by Savio D'Souza) via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment